


- A011104 \*\*SUSPENDED\*\*** ALLIANCE- Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer (**Feig**)
- UCI 15-83** Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting (**Tromberg**)
- UCI 10-39** Predicting, Pathologic Response w/in the 1<sup>st</sup> Week of Neoadjuvant ChemoTx Using Functional Parameters Measured Using Diffuse Optical Spectroscopic Imaging (**Tromberg**)
- UCI 11-15** Correlation of Clinical & MRI Finding w/ Prognosis of Breast CA Patients (**Su**)
- UCI 11-21** Analysis of Imaging Features of Breast Diseases and Breast Density Evaluated on Mammogram, Ultrasound & MRI Collected in a Database (**Su**)
- UCI 14-86** Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System (**Su**)
- UCI 14-85** Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System (**Su**)
- UCI 16-23** A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer –(WISDOM Study)-Women Informed to Screen Depending On Measures of Risk (**Anton-Culver**)

SCREENING/ DIAGNOSTIC/EPIDEMIOLOGIC/INTERVENTIONAL

**BREAST CANCER**

CORRELATIVE/ OBSERVATIONAL

- UCI 95-29** Measurement of Breast Optical properties (**Tromberg**)
- UCI 10-24** ATHENA Breast Health Network (**Anton-Culver**)
- UCI 12-10** Development of a Quantitative Tissue Optical Index of Breas Density for Prediction of Hormone Therapy Response (**O’Sullivan**)
- UCI 13-19** Registry Study of Patients Treated with Neoadjuvant Chemotherapy Followed by mastectomy in Stage I, II, III Breast Cancer (**Daroui**)
- UCI 14-25** Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (**Nelson**)
- UCI 14-36** A Correlative Study to Examine Cancer Molecular Alterations Using a Blood Based Assay (**Seery**)
- UCI 14-62** Breast Tumor Oxygenation During Exercise (**Tromberg**)
- UCI 14-81** A Self-discovery tool for Latina Breast cancer Survivors (**Sorkin**)
- UCI 15-64** A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery (**Police**)



### Multiple Disease Site

**UCI 17-50** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (**Ou**)

### Stage I-III

**UCI 14-67** A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel with Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting (**Mehta**)

**Adjuvant**

**Neo-Adjuvant**

<h3>HER2- High Risk</h3>			<h3>Hormone+ High Risk</h3>	
<p><b>SWOG S1207</b> Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer. (<b>Nangia</b>)</p>	<p><b>SWOG S1418</b> Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with &gt; 1 cm Residual Invasive Cancer or Positive Lymph Nodes (&gt;pN1mic) After Neoadjuvant Chemotherapy (<b>Nangia</b>)</p>	<p><b>Alliance A011502</b> A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial (<b>Nangia</b>)</p>	<p><b>NSABP B-54-I</b> Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients with Hormone-Receptor-Positive, HER2-Normal Primary Breast Cancer with High Relapse Risk after Neoadjuvant Chemotherapy "PENELOPE<sup>B</sup>" (<b>Nangia</b>)</p>	<p><b>NSABP B51</b> A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (<b>Daroui</b>)</p>

**Advanced**

**UCI 17-45** COMPLEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease (**Parajuli**)

**Metastatic**

**Targeted therapy**

**ECOG-EAY131** (MATCH)-Molecular Analysis for Therapy Choice (**Seery**)

**NRG BR002** A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer (**Daroui**)

**UCI 16-74** A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine (**Carrillo**)

